HAVCR2 protein inhibitors - Pipeline Insight, 2025

DelveInsight’s, “HAVCR2 protein inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 9+ pipeline drugs in HAVCR2 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

HAVCR2 protein inhibitors Understanding

HAVCR2 protein inhibitors: Overview

Hepatitis A virus cellular receptor 2 (HAVCR2), also known as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), is a protein that in humans is encoded by the HAVCR2 (TIM-3) gene. HAVCR2/TIM-3 is a transmembrane protein of T lymphocytes (CD4+ and CD8+ T cells), myeloid cells (monocytes, macrophages, DC, mast cells, NK cells) or various cells in different tumor types. The receptor is an immune checkpoint and together with other inhibitory receptors including programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG3) mediate the CD8+ T-cell exhaustion in terms of proliferation and secretion of cytokines such as TNF-alpha, IFN-gamma and IL-2. Combined blockade of HAVCR2 and PD-1 led to improved CD8+ T-cell response during the lymphocytic choriomeningitis virus infection.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence HAVCR2 protein inhibitors R&D. The therapies under development are focused on novel approaches for HAVCR2 protein inhibitors.

HAVCR2 protein inhibitors Emerging Drugs Chapters

This segment of the HAVCR2 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HAVCR2 protein inhibitors Emerging Drugs

• Sabatolimab: Novartis

Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. Sabatolimab is a first-in-class investigational immuno-myeloid therapy that binds to TIM-3, a novel target expressed on multiple immune cell types and leukemic cells and blasts, but not on the normal stem cells that induce blood formation; it is in development for HR-MDS and acute myeloid leukemia (AML).

• BMS 986258: Bristol-Myers Squibb

BMS 986258 (also known as ONO 7807) is a fully-human monoclonal antibody targeting T-cell immunoglobulin and mucin domain-3 (TIM-3 or HAVCR2) developed by Bristol-Myers Squibb. Currently, it is in Phase II stage of clinical trial evaluation to treat Solid tumours.

Further product details are provided in the report……..

HAVCR2 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different HAVCR2 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on HAVCR2 protein inhibitors

There are approx. 8+ key companies which are developing the HAVCR2 protein inhibitors. The companies which have their HAVCR2 protein inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

• Phases

DelveInsight’s report covers around 9+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

HAVCR2 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HAVCR2 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HAVCR2 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HAVCR2 protein inhibitors drugs.

HAVCR2 protein inhibitors Report Insights

• HAVCR2 protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

HAVCR2 protein inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing HAVCR2 protein inhibitors drugs?
• How many HAVCR2 protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HAVCR2 protein inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HAVCR2 protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for HAVCR2 protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Bristol-Myers Squibb
• BrightPath Biotherapeutics
• Symphogen
• Aurigene Discovery Technologies
• Incyte Corporation
• Eli Lilly and Company
• AnaptysBio

Key Products

• Sabatolimab
• BMS 986258
• BP 1210
• Sym 023
• MAS 825
• CA 327
• INCAGN 02390
• LY 3415244
• Cobolimab

Please Note: It will take 3-4 business days to complete the report upon order confirmation. Show more